Merck Reports Positive Results from Trials of Enlicitide, an Experimental Oral PCSK9 Inhibitor

Merck has announced promising results from two clinical trials evaluating enlicitide, an experimental oral medication designed to block the protein PCSK9. The drug demonstrated its ability to significantly reduce cholesterol levels in both studies, marking a potential breakthrough in cholesterol management. If approved, enlicitide would become the first oral treatment targeting PCSK9, a protein known for its role in regulating low-density lipoprotein (LDL) cholesterol levels.

The trials, which have garnered considerable attention within the medical community, assessed enlicitide’s efficacy and safety profile. Researchers observed notable reductions in LDL cholesterol among participants who received the medication. PCSK9 inhibitors are currently available only as injectable treatments; therefore, an oral alternative could represent a significant advancement in accessibility and convenience for patients managing high cholesterol. Further details regarding dosage regimens and long-term effects are expected to be explored in subsequent phases of research.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

Date: June 9, 2025

Related posts:

Data Clean Rooms Revolutionize Secure Healthcare Data Sharing Study Finds Timing of Prenatal Stress Influences Infant Stress Responses by Gender Shilpa Medicare Barred from FDA Approval for Generic Lenvatinib Mesylate Until 2036 Following Eisai Patent Ruling Metsera Reports Early Clinical Trial Success for Obesity Drug Targeting Amylin Hormone

Author

Mark Chiang